文献速递关节外科骨肿瘤

恶性肿瘤与关节置换术相关吗?一项Meta分析

Is Malignancy Associated With Arthroplasty? A Meta-analysis.
PubMed 文献 · Clin Orthop Relat Res · 2025-08-13

该系统综述与Meta分析纳入16项记录链接研究、977465例接受全髋或全膝关节置换术的患者,随访超过7415134人年,比较其总体癌症发生率与外部参考人群。结果显示,全髋或全膝关节置换术与癌症风险升高无关(合并随机效应估计值0.99,95%CI 0.92-1.07,p=0.88),金属对金属或骨水泥固定植入物及随访时长也未显示与癌症风险相关。作者认为,基于当前证据,临床医生可继续推荐关节置换术而无需额外担心癌症风险,但未来研究应确保更长随访、改善全球代表性并收集详细的患者和植入物特异性数据。

要点

  • 全髋或全膝关节置换术患者癌症风险与一般人群无差异(合并REE=0.99,95%CI 0.92-1.07,p=0.88)。
  • 金属对金属或骨水泥固定植入物未显示癌症风险升高(REE分别为1.02和1.00)。
  • 随访≥10年与<10年患者癌症风险均未升高,随访时长与癌症风险无关。

核心结论

  • 基于当前证据,临床医生可继续推荐关节置换术而无需额外担心癌症风险,但未来研究应确保更长随访、改善全球代表性并收集详细的患者和植入物特异性数据。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和SCOPUS从建库至2024年11月23日,纳入16项比较全髋或全膝关节置换术患者与外部参考人群总体癌症发生率的记录链接研究。
  • 纳入研究的纽卡斯尔-渥太华量表评分为6至8分(均值±标准差7.1±0.8),反映方法学质量总体较高。
  • 主要分析纳入977465例接受髋或膝关节置换术的患者,随访超过7415134人年,采用随机效应模型合并效应估计值。

主要发现

  • 全髋或全膝关节置换术患者与一般人群相比癌症风险未增加(合并随机效应估计值0.99,95%CI 0.92-1.07,p=0.88)。
  • 全膝关节置换术亚组癌症风险未增加(合并REE=1.02,95%CI 0.85-1.21,p=0.83),全髋关节置换术亚组亦未增加(合并REE=0.99,95%CI 0.91-1.07,p=0.73)。
  • 接受骨水泥固定植入物的全髋关节置换术患者癌症风险未增加(合并REE=1.00,95%CI 0.87-1.15,p=0.93),金属对金属植入物患者亦未增加(合并REE=1.02,95%CI 0.85-1.21,p=0.86)。
  • 随访≥10年患者癌症发生率与一般人群无差异(合并REE=1.05,95%CI 0.97-1.14,p=0.21),随访<10年患者亦未观察到癌症风险增加(合并REE=0.93,95%CI 0.81-1.06,p=0.27)。
  • Meta回归显示随访时长与癌症风险无关(β=-0.004,95%CI -0.024至0.015,p=0.66)。

关键数值与推荐

  • 全髋或全膝关节置换术与一般人群比较的合并随机效应估计值为0.99(95%CI 0.92-1.07,p=0.88)。
  • 全膝关节置换术亚组合并REE为1.02(95%CI 0.85-1.21,p=0.83),全髋关节置换术亚组合并REE为0.99(95%CI 0.91-1.07,p=0.73)。
  • 骨水泥固定植入物亚组合并REE为1.00(95%CI 0.87-1.15,p=0.93),金属对金属植入物亚组合并REE为1.02(95%CI 0.85-1.21,p=0.86)。
  • 随访≥10年亚组合并REE为1.05(95%CI 0.97-1.14,p=0.21),随访<10年亚组合并REE为0.93(95%CI 0.81-1.06,p=0.27)。

临床怎么用

  • 作者认为,基于当前证据,临床医生可继续推荐关节置换术而无需额外担心癌症风险。

局限性

  • 未来研究应确保更长随访、改善全球代表性并收集详细的患者和植入物特异性数据,以更好地描述潜在的罕见或长潜伏期恶性肿瘤。
  • 本研究未进行先验功效分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although implants have been linked to malignancies in other medical contexts, such as the relationship between anaplastic large cell lymphoma and breast implants, the potential association between orthopaedic implants and cancer remains unclear. Several studies have investigated this question, but findings have been inconsistent. A comprehensive meta-analysis is needed to clarify whether total joint arthroplasty increases the risk of malignancy. QUESTIONS/PURPOSES: (1) Is receiving a THA or TKA associated with an increased risk of cancer? (2) Are certain implant types (such as metal-on-metal or cemented) associated with increased cancer risk? (3) Is follow-up duration associated with changes in observed cancer risk estimates? METHODS: A systematic review and meta-analysis were conducted using PubMed, Embase, and SCOPUS to identify studies assessing cancer incidence rates in patients who received hip or knee arthroplasty compared to patients in control groups who did not receive arthroplasty. Databases were queried from inception through the final search date (November 23, 2024). Eligible studies reported or allowed derivation of an effect estimate comparing overall cancer incidence rates in recipients of THA or TKA with an external reference population. From 1838 screened articles, 16 studies were included, all of which provided extractable effect estimates that were entered into one or more of our meta-analyses. Included studies consisted primarily of record-linkage studies connecting national, longitudinally maintained arthroplasty registers to similarly longitudinal national mortality and cancer registers. Study quality was assessed using the Newcastle-Ottawa Scale, which awards up to nine points across three categories, with higher scores indicating lower risk of bias. The 16 included studies scored between 6 and 8 (mean ± SD 7.1 ± 0.8), reflecting generally high methodological quality. The primary analysis included data from 977,465 patients of both sexes and all age groups who underwent hip or knee arthroplasty and were followed up for over 7,415,134 person-years. Effect estimates were pooled with a random-effects model because heterogeneity was present (between-study σ 2 = 0.016 versus within-study σ 2 = 0.002; Q = 1195, p < 0.001), and a funnel plot showed no evidence of publication bias. To explore associations between implant type and cancer risk for patients undergoing THA, we conducted separate meta-analyses for studies reporting on metal-on-metal bearing surfaces and those reporting on cemented fixation. To assess latency effects, we compared cancer incidence rates in patients with more or less than 10 years of follow-up and conducted a meta-regression to evaluate the association between follow-up duration and cancer risk. We did not perform an a priori power analysis. RESULTS: Patients who underwent THA or TKA did not have an increased risk of cancer compared with the general population (pooled random-effects estimate [REE] = 0.99 [95% confidence interval (CI) 0.92 to 1.07]; p = 0.88). Subgroup analyses showed no increased cancer risk after TKA (pooled REE = 1.02 [95% CI 0.85 to 1.21]; p = 0.83) or THA (pooled REE = 0.99 [95% CI 0.91 to 1.07]; p = 0.73). Cancer risk did not increase among patients undergoing THA who received cemented implants (pooled REE = 1.00 [95% CI 0.87 to 1.15]; p = 0.93) or metal-on-metal implants (pooled REE = 1.02 [95% CI 0.85 to 1.21]; p = 0.86) compared with the general population. Among patients with ≥ 10 years of follow-up, cancer incidence did not differ from the general population (pooled REE = 1.05 [95% CI 0.97 to 1.14]; p = 0.21); similarly, among patients with < 10 years of follow-up, no increased cancer risk was observed (pooled REE = 0.93 [95% CI 0.81 to 1.06]; p = 0.27). Meta-regression showed no association between follow-up duration and cancer risk (β = -0.004 [95% CI -0.024 to 0.015]; p = 0.66). CONCLUSION: Based on these findings, clinicians can continue to recommend arthroplasty without additional cancer-related concern based on current evidence. However, future studies should ensure longer follow-up, improved global representation in large linkage studies, and detailed patient- and implant-specific data to better characterize potential rare or long-latency malignancies. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Johnstone T, Sayadi JJ, Arora JS, et al. Is Malignancy Associated With Arthroplasty? A Meta-analysis. Clin Orthop Relat Res. 2025. PMID: 40828988. doi:10.1097/CORR.0000000000003654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。